Diosmin or Rebamipide as Add‑ons to Standard RA Therapy
Official title: Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis
Run by Tanta University · NCT07745426 · Data updated 2026-11-12
This study tests whether adding diosmin or rebamipide to standard rheumatoid arthritis therapy helps patients achieve better control of their disease compared with standard therapy alone.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | August 1, 2027 |
| Study ends | August 1, 2027 |
| Registry record updated | August 4, 2026 |
| Trial ID | NCT07745426 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with active rheumatoid arthritis (DAS-28 > 2.6) already on conventional DMARDs.
✕Probably not a fit
Patients not responding to added diosmin or rebamipide or who experience adverse effects may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, parallel‑group Phase 2 trial enrolling 66 adults with active rheumatoid arthritis. Participants will be assigned to receive conventional RA therapy alone, or with an added daily 1000 mg diosmin, or with 100 mg rebamipide three times daily for 3 months. All participants will continue to receive standard DMARDs; outcomes will focus on changes in disease activity and safety. The trial is conducted at Tanta University in Egypt and uses standard ACR/EULAR criteria for eligibility.
Why it matters
Potential benefit: If successful, adding diosmin or rebamipide could offer an extra option to improve disease control for patients on conventional RA therapy.
How similar studies have gone: Prior research on diosmin or rebamipide as RA adjuncts is limited; this study explores a novel combination in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) \>2.6. * Both sexes. * Age ranges between 18 and 70 years old. * Patients receiving conventional DMARDs Exclusion Criteria: * Pregnant and lactating females. * Patients receiving biological DMARDs or targeted synthetic DMARDs. * Patients with renal and hepatic dysfunction. * Patients with other inflammatory/autoimmune diseases, active infection, or malignancies. * Patients with bleeding disorders, receiving warfarin or other anticoagulants. * Patients receiving antioxidants. * Patients with hypersensitivity to study medications.
Where it's running
-
Faculty of Pharmacy Tanta University
Tanta, Egypt Recruiting
Study contacts
- Study coordinator: khlood mohamed kettana, assistant lecturer
- Email: khlood.kettana@pharm.tanta.edu.eg
- Phone: 01091100037
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.